BioTuesdays

Tag - OPS

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.